Skip to main content
SpringerLink
Log in

Statin cost effective for CVD prevention in T2DM in China

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was partially funded by Pfizer Inc.

Reference

  • Li T, et al. Cost-Effectiveness of Primary Prevention with Statin Treatment for Chinese Patients with Type 2 Diabetes. Advances in Therapy : 2 Nov 2018. Available from: URL: http://doi.org/10.1007/s12325-018-0823-9

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Statin cost effective for CVD prevention in T2DM in China. PharmacoEcon Outcomes News 816, 28 (2018). https://doi.org/10.1007/s40274-018-5448-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-018-5448-3

Search

Navigation